Improving Psoriatic Arthritis Screening for Patients with Plaque Psoriasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to enhance the screening process for psoriatic arthritis (PsA) by adding two questions and images to the existing PEST questionnaire for patients with moderate-to-severe plaque psoriasis. Participants will complete the screening at their first dermatologist visit, and those who screen positive will undergo a comprehensive diagnostic assessment by a rheumatologist. The study will track treatment choices and status through a remote follow-up visit with the dermatologist. The goal is to improve early diagnosis and treatment pathways for patients with PsA.

Why it matters

Who can join: the full rules

Key inclusion criteria:

1. Moderate-to-severe plaque PsO patients who are candidates for bDMARDs, according to physician's clinical judgement at the time of patient enrollment.
2. Adult patients at the time of informed consent signature
3. Patients able to understand and willing to comply with protocol requirements, instructions, and restrictions
4. Residents of Canada

Key exclusion criteria:

1. Patients who have previously screened positive for PsA through PEST.
2. Patients who have been diagnosed with PsA.
3. Patients who have been diagnosed with inflammatory arthritis unrelated to PsA (rheumatoid arthritis, reactive arthritis, enteropathic arthritis, axial spondyloarthritis)
4. Patients treated with a bDMARD for moderate-to-severe plaque PsO or any other medical condition within the last 6 months prior to patient enrollment.

Where it's running

• Novartis Investigative Site
  Calgary, Alberta, Canada Recruiting
• Novartis Investigative Site
  Edmonton, Alberta, Canada Recruiting
• Novartis Investigative Site
  Edmonton, Alberta, Canada Recruiting
• Novartis Investigative Site
  Kelowna, British Columbia, Canada Recruiting
• Novartis Investigative Site
  Surrey, British Columbia, Canada Recruiting
• Novartis Investigative Site
  Winnipeg, Manitoba, Canada Recruiting

Study contacts

• Study coordinator: Novartis Pharmaceuticals
• Email: novartis.email@novartis.com
• Phone: +41613241111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How safe and well ZP9830 works in people with plaque psoriasis over 8 weeks

  This study tests whether ZP9830 is safe and tolerable in adults with plaque psoriasis for 8 weeks, with a comparison to placebo.

  Recruiting Phase 1 Zealand Pharma · Leiden, South Holland · NCT07733089

• HLA B Leader in Psoriatic Arthritis

  This study tests whether the HLA B leader gene is more common in people with psoriatic arthritis than in healthy individuals.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens, Picardie · NCT07718815

• Secukinumab retention in adults with plaque psoriasis and MASLD in Spain

  This study tests how long people with plaque psoriasis and MASLD stay on secukinumab in real-world Spain, using EMR data from several hospitals.

  Recruiting at 9 sites Novartis · Badalona, Barcelona and 8 other locations · NCT07683065

• TaVNS for Psoriatic Arthritis in Adults

  This study tests whether non-invasive taVNS can help reduce disease activity and improve pain and quality of life in adults with psoriatic arthritis.

  Recruiting Marmara University · Istanbul · NCT07653009

• Long-term ORKA-001 treatment for adults with plaque psoriasis

  This open-label extension will try ORKA-001 long-term in adults with moderate-to-severe plaque psoriasis who completed a previous ORKA-001 study.

  Recruiting at 39 sites Phase 2 Oruka Therapeutics, Inc. · Phoenix, Arizona and 38 other locations · NCT07449702

• TQH3906 capsules for active psoriatic arthritis in adults

  This trial tests whether TQH3906 capsules help people with active psoriatic arthritis more than a placebo over 12 weeks.

  Recruiting at 36 sites Phase 2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Bozhou, Anhui and 43 other locations · NCT07406035

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.